Skip to main content
. 2009 Jun;174(6):2061–2072. doi: 10.2353/ajpath.2009.080960

Figure 3.

Figure 3

Influence of metalloproteinase inhibitors on the expression of soluble and cellular CXCL16 in human podocytes in the presence of IFN-γ or TNF-α. A: Effects of different metalloproteinase inhibitors on the IFN-γ release of CXCL16 (18 hours treatment). Fifteen minutes prior to IFN-γ treatment, the cells were preincubated with 3 μmol/L GW280264X (GW), 3 μmol/L GI254023X (GI), 50 μmol/L GM6001 (GM), or 20 μmol/L TAPI-2. All data were reproduced in three independent experiments and are represented as mean ± SE (n = 3). *P < 0.05 considered statistically significant compared with the control; #P < 0.05, considered statistically significant compared with the IFN-γ treated cells. B: Soluble CXCL16 was measured in supernatants of podocytes treated for 18 hours with TNF-α. Fifteen minutes prior to TNF-α treatment, cells were preincubated with 3 μmol/L GW280264X (GW), 3 μmol/L GI254023X (GI), 50 μmol/L GM6001 (GM), or 20 μmol/L TAPI-2. All data were reproduced in three independent experiments and are represented as mean ± SE (n = 3). **P < 0.01 considered statistically significant compared with the control; #P < 0.05, ##P < 0.01 considered statistically significant compared with the TNF-α treated cells. C and D: Western blot analysis of cellular CXCL16 in human podocytes after the application of different metalloproteinase inhibitors in the presence of IFN-γ (C) or TNF-α (D). E and F: Cellular CXCL16 protein levels were determined by ELISA in podocytes treated with different metalloproteinase inhibitors in the presence of IFN-γ (E) or TNF-α (F). All data were reproduced in three independent experiments and are represented as mean ± SE (n = 3). *P < 0.05 considered statistically significant compared with the cells grown in serum-free medium (control). #P < 0.05 considered statistically significant compared with IFN-γ- or TNF-α-treated cells.